When to Choose GHK-Cu Alone Standalone GHK-Cu is appropriate for researchers who are studying GHK-Cu's specific mechanisms in isolation, need to control for variables by using a single compound, are conducting dose-response studies on GHK-Cu specifically, or are researching GHK-Cu's gene expression modulation independent of other peptide activity
Titrate: Move to 200 mg per dose (100 units, 1.0 mL) from week 3 onward as tolerated
The peptide's efficacy against high-SASP senescent cells proves particularly valuable in the kidney microenvironment, where inflammatory signaling from senescent tubular cells impairs filtration and promotes fibrosis
Always patch test before first use (apply on jawline for 24 hours)
With pivotal data published in the New England Journal of Medicine, a missed head-to-head endpoint against Eli Lillys tirzepatide, and fresh diabetes results presented in June 2026, the CagriSema FDA review carries unusual complexity for a drug that has already reset expectations across the weight management field